Aimmune financials
WebAug 31, 2024 · Aimmune agreed to make upfront payments to Xencor of $5 million cash and $5 million in equity (156,238 newly-issued shares of Aimmune common stock at $32 a share)—plus up to $385 million in... WebAimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a ...
Aimmune financials
Did you know?
Web201 to 500 Employees. Type: Company - Public. Industry: Biotech & Pharmaceuticals. Revenue: Unknown / Non-Applicable. Competitors: Unknown. Taking Aim at Food Allergies Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies. WebAug 31, 2024 · Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it …
WebAimmune Therapeutics financials, including financial statements for 2024, basic ratios, indicators and analysis of Aimmune Therapeutics financial accounts and its historical … WebOct 14, 2024 · Oct 14, 2024. Back to Press releases. Vevey, Switzerland, Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc …
WebAimmune Therapeutics has raised a total of $540M in funding over 5 rounds. Their latest funding was raised on Feb 5, 2024 from a Post-IPO … WebJul 30, 2024 · Aimmune Therapeutics (AIMT) came out with a quarterly loss of $1.06 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.01 per share a year ago. These figures are...
WebNov 29, 2024 · The acquisition of Aimmune extended Nestlé’s reach into healthcare, which is Schneider’s background. He joined the group from German healthcare company …
WebNov 30, 2024 · While Nestlé CEO Mark Schneider touted the company’s “consistent financial results” over the past few years despite “living in a very volatile and turbulent environment” thanks partly ... save video from internet to computerWebAimmune’s Profile, Revenue and Employees. Aimmune is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of food allergies. … scaffold boards nottinghamWebAug 31, 2024 · NHSc currently has a total investment in Aimmune of USD473 million, an approximate 25.6% equity ownership stake. Around 19.6% is voting common stock and the balance non-voting preferred stock ... save vk downloadWebAug 31, 2024 · Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around... save vods twitchWebAddress: BLOCK B THE CRESCENT BUILDING NORTHWOOD CRESCENT NORTHWOOD SANTRY DUBLIN 9 SANTRY,DUBLIN, D09C6X8 Ireland See other locations Website: www.aimmune.com Employees (this site): Actual Revenue: Actual Fiscal Year End: Year Started: Incorporated: What is D&B's ESG Ranking? Is this your business? save video from twitter messageWebAug 31, 2024 · Nestl é Health Science has agreed to acquire Aimmune Therapeutics, the developer of the peanut allergy treatment Palforzia, in a deal that values the California … save videos from youtube to computersave view template revit